Full video transcriptClick to expand
Auto-generated transcript of @thedeltoro_life's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Because of ozimpic
- 0:04Imagine me coming up and going hey guys. I got some news for you
- 0:13I'm happy I would lose my mind. I will lose my mind
- 0:27You know when me and William first got together
- 0:31So my money you said oh my god if you could would you pop one out?
- 0:35We lost our minds for just a second. I'm gonna tell you right
- 0:39We lost our minds for one damn second
- 0:43Because William was like oh my god our babies would be so busy
- 0:48Hey kept on talking about that. He's kept saying oh my god, baby. We would have such beautiful baby. Dude. You're 61
- 0:58Or 60 at the time I met him
- 1:01I'm 53
- 1:04My kids would kill me. Okay
- 1:07So yes, then I was like
- 1:20What would we make we were talking about that y'all I got all A's I got Aria. Oh, I got Alex Ashton
- 1:29Aria
- 1:30So we were like what about August
- 1:34Because if I was to have a baby I'd get pregnant in August
Ozempic babies: separating viral anecdote from reproductive science
Quick answer
The video references the "Ozempic babies" phenomenon without making direct clinical claims. The relevant medical context is that GLP-1 receptor agonists, including semaglutide, may restore ovulatory function in women with obesity or PCOS, leading to unplanned pregnancies. Semaglutide carries teratogenicity warnings based on animal data and should be discontinued at least two months before a planned pregnancy per FDA prescribing guidance.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic babies: separating viral anecdote from reproductive science, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic babies: separating viral anecdote from reproductive science" from Constance. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video references the "Ozempic babies" phenomenon without making direct clinical claims.
The reason this review is not generic is the source wording and the canonical claim label "glp1 anybody having ozempic babies tell us your story catch our n." In this clip, the useful excerpt is: "Because of ozimpic Imagine me coming up and going hey guys." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The video references the "Ozempic babies" phenomenon without making direct clinical claims.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video references the "Ozempic babies" phenomenon without making direct clinical claims. The relevant medical context is that GLP-1 receptor agonists, including semaglutide, may restore ovulatory function in women with obesity or PCOS, leading to unplanned pregnancies. Semaglutide carries teratogenicity warnings based on animal data and should be discontinued at least two months before a planned pregnancy per FDA prescribing guidance.
- Semaglutide is not FDA-approved for fertility treatment and should not be used as one.
- A 2021 review by Joham et al. in Seminars in Reproductive Medicine confirmed that 5-10% weight loss can restore ovulatory cycles in women with PCOS, which may partly explain the fertility effect.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide is not FDA-approved for fertility treatment and should not be used as one.
- A 2021 review by Joham et al. in Seminars in Reproductive Medicine confirmed that 5-10% weight loss can restore ovulatory cycles in women with PCOS, which may partly explain the fertility effect.
- Animal studies cited in the Ozempic prescribing label show fetal harm at clinically relevant doses. Novo Nordisk recommends stopping the drug at least two months before a planned pregnancy.
- Women of reproductive age starting a GLP-1 medication should discuss contraception with their prescriber, particularly if they have been told pregnancy is unlikely due to PCOS or obesity.
- Compounded semaglutide products have no pregnancy safety data whatsoever, making the risk profile during unplanned pregnancies even less understood than with brand-name formulations.
- The "Ozempic babies" social media trend reflects a real but poorly publicized clinical phenomenon. A 2023 case series documented unexpected conceptions in women on semaglutide who had prior fertility difficulties.
- No randomized controlled trial has confirmed that GLP-1 drugs directly improve fertility independent of weight loss. The biology is plausible, but the evidence base is still early-stage.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @thedeltoro_life actually say?
This is mostly a personal story, not a medical claim. The creator shared a lighthearted conversation with her partner about what it would be like to get pregnant on Ozempic, joking about baby names and the absurdity of having a child at 53 while her partner is 61. She referenced the broader "Ozempic babies" phenomenon circulating on social media, but she did not personally claim to be pregnant or endorse the idea.
To be fair, she's riffing on a real cultural moment. The phrase "Ozempic babies" has spread widely on TikTok and Reddit, referring to unplanned pregnancies in women who were previously struggling with fertility, often due to polycystic ovary syndrome (PCOS), and who started semaglutide for weight management. The creator is engaging with that conversation humorously, not spreading clinical misinformation. That matters when we assess what's actually being claimed here.
Does the science back this up?
The underlying biology behind "Ozempic babies" is real, even if the social media framing is chaotic. GLP-1 receptor agonists like semaglutide appear to influence fertility in ways that researchers are still working to understand, particularly in women with obesity or PCOS. The mechanism is not fully established, but it likely involves multiple pathways.
Weight loss itself is well-documented to restore ovulatory function in women with PCOS. A 2021 review by Joham et al. in Seminars in Reproductive Medicine confirmed that even modest weight loss of 5-10% can restore regular menstrual cycles. Beyond that, GLP-1 receptors are expressed in ovarian tissue, and some researchers have proposed direct effects on ovarian function independent of weight loss. A 2023 case series published in The Journal of Clinical Endocrinology and Metabolism documented unexpected pregnancies in women on semaglutide who had previously been told they were unlikely to conceive. The FDA label for Ozempic does not address fertility explicitly, but it does advise discontinuing the drug at least two months before a planned pregnancy due to teratogenicity concerns in animal studies.
What did they get wrong (or right)?
The creator didn't really make a factual claim to get wrong. She named the trend accurately, engaged with it self-deprecatingly, and never suggested Ozempic boosts fertility as a treatment. That's a better batting average than most GLP-1 content on TikTok.
What she did not address, and what viewers watching this content deserve to know, is that the "Ozempic baby" pattern carries a serious clinical warning. Women on semaglutide who become pregnant unexpectedly may not realize the risk. Animal studies have shown semaglutide causes fetal harm at doses relevant to human use. Novo Nordisk's prescribing information explicitly warns against use during pregnancy. If the fertility effect is real, that creates a genuine public health gap: women who believe they cannot conceive may not be using contraception, and semaglutide removes that assumption faster than anyone expects.
The humor here is harmless. The underlying gap in awareness is not.
What should you actually know?
If you are on a GLP-1 medication and of reproductive age, this is information you need from your prescriber, not TikTok. The evidence that semaglutide can restore fertility, particularly in women with PCOS or obesity-related cycle disruption, is plausible and growing. But the drug is not approved as a fertility treatment, and the research is nowhere near strong enough to treat it as one.
Three things are worth knowing clearly:
- GLP-1 drugs have not been studied in pregnant women. The safety data comes from animal models, and it is not reassuring.
- Restored fertility can happen faster than expected. Women who have been told conception is unlikely should discuss contraception with their provider when starting a GLP-1 medication.
- Compounded semaglutide products, which many patients are using due to cost and access issues, have not been tested for safety during pregnancy at all. The risks are unknown and potentially greater than with FDA-approved formulations.
The creator's instinct, that this is funny and a little wild, is fair. The clinical reality is that it also warrants a direct conversation with your doctor before you're surprised by a positive test.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Constance · TikTok creator
6.9K views on this video
Anybody having Ozempic Babies? Tell us your story! 😂 Catch our next “Real Talk Live”. So much Fun! 😂 #LIVEhighlights #TikTokLIVE #LIVE
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide?
Semaglutide is not FDA-approved for fertility treatment and should not be used as one.
What does the video say about a 2021 review by joham et al. in seminars in?
A 2021 review by Joham et al. in Seminars in Reproductive Medicine confirmed that 5-10% weight loss can restore ovulatory cycles in women with PCOS, which may partly explain the fertility effect.
What does the video say about animal studies cited in the ozempic prescribing label show fetal?
Animal studies cited in the Ozempic prescribing label show fetal harm at clinically relevant doses. Novo Nordisk recommends stopping the drug at least two months before a planned pregnancy.
What does the video say about women of reproductive age starting a glp-1 medication should discuss?
Women of reproductive age starting a GLP-1 medication should discuss contraception with their prescriber, particularly if they have been told pregnancy is unlikely due to PCOS or obesity.
What does the video say about compounded semaglutide products have no pregnancy safety data whatsoever, making?
Compounded semaglutide products have no pregnancy safety data whatsoever, making the risk profile during unplanned pregnancies even less understood than with brand-name formulations.
What does the video say about the "ozempic babies" social media trend reflects a real?
The "Ozempic babies" social media trend reflects a real but poorly publicized clinical phenomenon. A 2023 case series documented unexpected conceptions in women on semaglutide who had prior fertility difficulties.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Constance, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.